| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bcd1a4c6b2279d424596632903987de6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_65a845854bafa128c237db82c52534bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb16868ca5db369db4ce1e1335a1a45b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e60553297b92732fc4993fe9e0132b1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9d24fd34628cf50e1fd8f096816e692b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5eee65be3b80eb7c9b1e55411638ecef |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-71 |
| filingDate |
2012-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b8541c199b30f71c9ef1becd7bc4321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_adea970602c5a834ce1561676b400cb9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9eb5ac3ebcbc9bb1229750dad8c0868e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e74999c645bab4cdea912cd3df385bf2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4575244d88f09e99fcc85c6e93a999ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b1601f7dc7c9521e95c178275b6d622 |
| publicationDate |
2013-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2489160-C1 |
| titleOfInvention |
Method for prevention of foetus pathology in pregnant women suffering acute respiratory viral infections |
| abstract |
FIELD: medicine. n SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and may be used for preventing a foetus pathology in pregnant women suffering acute respiratory viral infections. That is ensured by the vitamin therapy according to the daily dosages. The therapy is combined with the additional antihomotoxic therapy with the preparation Traumel C 2.2 ml intravenously every second day over a period of the clinical manifestations of the ARVI, and with the preparation Engystol for 6 weeks from the beginning of the disease - 1 tablet 3 times a day for the first 2 weeks. Then 1 tablet is taken 2 times a day for the following 2 weeks. Then 1 tablet is taken 1 time a day for the last 2 weeks. n EFFECT: method is safe for the pregnant woman's and foetus's health; it is available, provides the more effective prevention of a perinatal pathology caused by the acute respiratory viral infection in the women during gestation. |
| priorityDate |
2012-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |